A Russian model for evaluating the efficiency of the sFlt-1/PlGF test for preeclampsia

Objective. To study the Russian model for evaluating the efficiency of the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) test versus standard practice for preeclampsia (PE) in the second half of pregnancy. Material and methods. Based on the data of foreign studies on the nature of the flow of patients with PE, the national statistics of the Russian Federation, national clinical guidelines and protocols for a given algorithm of mathematical formulas (MS excel 2016), the outcomes were modeled taking into account the use of the sFlt-1/ PlGF test (Elecsys/Cobas, Roche Diagnostics, Rotkreuz, Switzerland) for the diagnosis of PE. Results. Analysis of priority publications, as well as mathematical modelling with the introduction of correction factors to the European models demonstrated the advantages of using the innovative sFlt-1/PlGFtest in risk-group patients with symptomatic and asymptomatic pregnancy in the diagnosis of PE, reducing the risk of severe forms of the disease, which led to fetal growth restriction, premature birth, and perinatal mortality. Conclusion. The mathematical modeling data on the use of the innovative sFlt-1/PlGF test in the second half of pregnancy confirm its efficiency in the diagnosis and prediction of PE.

sFlt-1/PlGF, preeclampsia, eclampsia, modelling, statistical indicators for types of preeclampsia, pregnancy, sFlt-1/ PlGF, prediction of preeclampsia, diagnosis of preeclampsia